On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...